MedTrace Logo

Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

NCT05655078 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2026-03-30

No results posted yet for this study

Summary

Phase III randomised-controlled trial for patients with unilateral malignant pleural mesothelioma (MPM).

Conditions

  • Malignant Pleural Mesothelioma

Interventions

RADIATION

Proton beam therapy

5 weeks (Mon-Fri) of proton beam treatment to the hemithorax to a dose of 50Gy in 25 fractions with a boost to 60Gy for the visible tumour (gross tumour volume-GTV).

Sponsors & Collaborators

  • Asthma + Lung UK

    collaborator UNKNOWN

  • Mesothelioma UK

    collaborator UNKNOWN

  • University of Sheffield

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • Crispin Hiley · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-28
Primary Completion
2029-03-31
Completion
2029-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05655078 on ClinicalTrials.gov